medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2008, Número 5

<< Anterior Siguiente >>

Rev Invest Clin 2008; 60 (5)


La infección por el virus del papiloma humano y cáncer cervicouterino: una perspectiva de salud pública

Torres-Poveda KJ, Burguete A, Bermúdez-Morales VH, Madrid-Marina V

Idioma: Español
Referencias bibliográficas: 56
Paginas: 414-420
Archivo PDF: 70.33 Kb.


FRAGMENTO

Mujer de 46 años, casada, ama de casa, analfabeta, de origen étnico náhuatl, originaria y residente de la Sierra de Puebla. Con antecedentes oncológicos heredo-familiares negativos. Antecedentes ginecoobstétricos: menarca a los 13 años; ritmo 30x3; FUM: 41 años; IVS: 13 años, parejas sexuales: dos, G: 13, P: 12, C: 0, A: 1; EPP: 18 años; EUP: 37 años; hormonales negativos; DOCMA: nunca. Papanicolau: nunca. Padecimiento actual: paciente que refirió un mes de evolución con sangrado transvaginal en moderada cantidad, intermitente, sin ninguna otra sintomatología; por lo que acudió al servicio de colposcopia, de donde fue enviada a la unidad de oncología.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Jones SB. Cancer in the developing world: a call to action. BMJ 1999; 3(19): 505-8.

  2. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide. Version 1.0. IARC Cancer Base No 5. Lyon: IARC Press, 2001. Edición limitada disponible en http://www.dep.iarc.fr/globocan/ globocan.htm.

  3. Palacio LS, Rangel G, Hernandez M, Lazcano E. Cervical cancer a disease of poverty: mortality differences between urban and rural areas in México. Salud Pública Mex 2003; 45: S376-S387.

  4. Posso H. Carga de cánceres asociados con el VPH en América Latina. Newsletter on Human Papillomavirus. HPV Today 2007; 12: 3.

  5. Lewis MJ. Análisis de la situación del cáncer cérvicouterino en América Latina y el Caribe. Washington, D.C. Organización Panamericana de la Salud/Organización Mundial de la Salud (OPS/OMS); 2004, p. 40.

  6. Arossi S, Sankaranarayanan R, Parkini D. Incidence and mortality of cervical cancer in Latin America. Salud Pública Mex 2003; 45: S306-S314.

  7. Lazcano E, Herrero R, Muñoz N, Cruz A, Shah KV, Alonso P, et al. Epidemiology of HPV infection among Mexican women with normal cervical cytology. Int J Cancer 2001; 91: 412-20.

  8. Flores YI, Dishai D, Lazcano E, Shah K, Lorincz A, Hernandez M, et al. Improving cervical cancer screening in Mexico: results from the Morelos HPV study. Salud Pública Mex 2003; 45: S388-S398.

  9. Franco EL, Rohan TE, Villa LL. Epidemiologic Evidence that Human Papillomavirus Infection as a Necessary Cause of Cervical Cancer. J Natl Cancer Inst 1999; 91(6): 506-11.

  10. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189(1): 12-9.

  11. Ho GY, Kadish AS, Burk RD, Basu J, Palan PR, Mikhail M, et al. HPV 16 and cigarette smoking as risk factors for high-grade cervical intra-epithelial neoplasia. Int J Cancer 1998; 78(3): 281-5.

  12. Moscicki AB, Shiboski S, Broering J. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 1998; 132(2): 277-84.

  13. Schiffman MH, Bauer HM, Hoover RN, Glass AG, Cadell DM, Rush BB, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993; 85: 958-64.

  14. Evander M, Gustafsson A. Human papillomavirus infection is transient in young women: a population-based cohort study. J Infect Dis 1995; 171(4): 1026-30.

  15. Muñoz N, Franceschi S, Bosetti C, Moreno NV, Herrero R, Smith JS, et al. Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet 2002; 359(9312): 1093-101.

  16. Smith JS, Green J, Berrington DG, Appleby P, Peto J, Plummer M, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 2003; 361: 1159-67.

  17. Castellsague X, Munoz N. Cofactors in human papillomavirus carcinogenesis role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr 2003; 31: 20-8.

  18. Clarke B, Chetty R. Postmodern cancer: The role of human immunodeficiency virus in uterine cervical cancer. Mol Pathol 2002; 55(1): 19-24.

  19. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci 2006; 110: 525-41.

  20. Persson G, Andersson K, Krantz I. Symptomatic genital papillomavirus infection in a community. Incidence and clinical picture. Acta Obstet Gynecol Scand 1996; 75: 287-90.

  21. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348(6): 518-27.

  22. Molijn A, Kleter B, Quint W, Van Doorn LJ. Molecular diagnosis of human papillomavirus (HPV) infections. J Clin Virol 2005; 32: S43-S51.

  23. Doorbar J, Cubie H. Molecular basis for advances in cervical screening. Mol Diag 2005; 9(3): 129-42.

  24. Frattini MG, Hurst SD, Lim HB, Swaminathan S, Laimins LA. Abrogation of a mitotic checkpoint by E2 proteins from oncogenic human papillomaviruses correlates with increased turnover of the p53 tumor suppressor protein. EMBO J 1997; 16(2): 318-31.

  25. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV- 16 E6 and E6-AP complex functions as an ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993; 75(3): 495-505.

  26. Scheffner M, Romanczuk H, Munger K, Huibregtse JM, Mietz JA, Howley PM. Functions of human papillomavirus proteins. Curr Topics Microbiol Immunol 1994; 186: 83-99.

  27. Foster SA, Demers GW, Etcheid BG, Galloway DA. The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest. J Virol 1994; 68: 5698-705.

  28. Chen CH, Shyu M, Au L, Chu H, Cheng W, Choo K. Analysis of detection of the integrated human papillomavirus 16 sequence in cervical cancer: A rapid multiplex polimerase chain reaction approach. J Med Virol 1994; 44: 206-21.

  29. Mota F, Rayment N, Chong S, Singer A, Chain B. The antigenpresenting environment in normal and human papillomavirus (HPV)-related premalignant cervical epithelium. Clin Exp Immunol 1999; 116(1): 33-40.

  30. Bermudez VH, Peralta O, Madrid-Marina V. Gene therapy with cytokines against cervical cancer. Salud Pública Mex 2005; 47(6): 458-68.

  31. Clerici M, Merola M, Ferrario E, Trabattoni D, Villa ML, Stefanon B, et al. Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection. J Natl Cancer Inst 1997; 89: 245-50.

  32. Elsässer-Beile U, Von Kleist S, Sauther W, Gallati H, Mönting JS. Impaired cytokine production in whole blood cell cultures of patients with gynecological carcinomas in different clinical stages. Br J Cancer 1993; 68(1): 32-6.

  33. Giannini SL, Hubert P, Doyen J, Boniver J, Delvenne P. Influence of the mucosal epithelium microenvironment on Langerhans cells: implications for the development of squamous intraepithelial lesions of the cervix. Int J Cancer 2002; 97(5): 654-9.

  34. Alcocer JM, Berumen J, Tamez R, Bermudez VH, Peralta O, Hernández R, et al. In vivo expression of immunosuppressive cytokines in human papillomavirus-transformed cervical cancer cells. Viral Immunol 2006; 19: 481-91.

  35. De Gruijl TD, Bontkes HJ, Van den Muysenberg AJC, Van Oostveen JW, Stukart MJ, Verheijen RHM, et al. Differences in cytokine mRNA profiles between pre-malignant and malignant lesions of the uterine cervix. Eur J Cancer 1999; 35: 490-7.

  36. Bermúdez-Morales VH, Burguete AI, Gutiérrez ML, Alcocer- González JM, Madrid-Marina V. Correlation between IL-10 expression and Human Papillomavirus infection in cervical cancer. A Mechanism for Immune Response Escape. Cancer Investig 2008 (En prensa).

  37. Peralta O, Recillas F, Alcocer JM, Bermudez VH, Madrid-Marina V. Human papilomavirus-16 E6 and E7 proteins induce activation of human TGF-β1 basal promoter in epithelial cells throughout a Sp1 recognition sequence. Viral Immunol 2006; 19(3): 468-80.

  38. Díaz CE, Flores JA, Navarro KR, Juárez J, Alcocer JM, Madrid- Marina V. TGF-β1 and IL-10 inhibit T lymphocytes proliferation and CD3-ζ expression in women with cervical cancer. UICC World Cancer Congress; 2006, p. 41-5.

  39. Gariglio P, Benitez L, Berumen J, Alcocer JM, Tamez R, Madrid- Marina V. Therapeutic Uterine-Cervix Cancer Vaccines in Humans. Arch Medical Research 1998; 29(4): 279-84.

  40. Wang SS, Hildesheim A. Viral and Host Factors in Human Papillomavirus Persistence and Progression. J Natl Cancer Inst Monogr 2003; 31-5.

  41. Hildesheim A, Wand SS. Host and viral genetics and risk of cervical cancer: a review. Virus Res 2002; 89(2): 229-40.

  42. Apple RJ, Erlich HA, Klitz W, Manos MM, Becker TM, Wheeler CM. HLA DR-DQ associations with cervical carcinoma show papilomavirus-type specificity. Nat Genet 1994; 6(2): 157-62.

  43. Koushik A, Ghosh A, Duarte E, Forest P, Voyer H, Matlashewski G, et al. The p53 codon 72 polymorphism and risk of high-grade cervical intraepithelial neoplasia. Cancer Detect Prev 2005; 29(4): 307-16.

  44. Jee SH, Won SY, Yun JE, Lee JE, Park JS, Ji SS. Polymorphism p53 codon-72 and invasive cervical cancer: a metaanalysis. Int J Gynaecol Obstet 2004; 85(3): 301-8.

  45. Hutchinson IV, Turner DM, Sankaran D, Awad MR, Sinnott P. Influence of cytokine genotypes on allograft rejection. Transp Proc 1998; 30: 862.

  46. Grainger DJ, Heathcote K, Chiano M, Snledor H, Kemp PR, Metcalfe JC, et al. Genetic control of the circulating concentration of transforming growth factor type beta-1. Hum Mol Gen 1999; 8: 93.

  47. Kersemaekers A, Van de Vijver M, Kenter GG, Fleuren GJ. Genetic alterations during the progression of squamous cell carcinomas of the uterine cervix. Genes Chromosomes and Cancer 1999; 26: 346.

  48. Harima Y, Sawada S, Nagata K, Sougawa M, Ohnishi T. Chromosome 6p21.2, 18q21.2 and human papillomavirus (HPV) DNA can predict prognosis of cervical cancer after radiotherapy. Int J Cancer 2001; 95: 286.

  49. Bermúdez-Morales VH, Alcocer-González JM, Peralta-Zaragoza O, Moreno J, Madrid-Marina V. Human papillomavirus 16 E2 protein bind to a putative E2 regulatory element in the human IL-10 gene promoter and induces interleukin 10 expression in cervical cancer cells. Cancer Investig 2008 (Enviado).

  50. Mahon SM. Prevention and Early Detection of Cancer in Women. Sem in Oncol Nurs 1995; 11(2): 88-102.

  51. McLemore MR. Gardasil: Introducing the new human papillomavirus vaccines. Clin J Oncol Nurs 2006; 10: 559-60.

  52. Shi L, Sings HL, Bryan JT, Wang B, Wang Y, Mach H, et al. GARDASIL®: Prophylactic human papillomavirus vaccine development from bench top to bed-side. Clin Pharmacol Ther 2007; 81: 259-64.

  53. Simon P, Dupond I. Anti-HPV vaccination: preventing cervical cancer. Rev Med Brux 2006; 27: S338-S340.

  54. Hanna E, Bachmann G. HPV vaccination with Gardasil: a breakthrough in women’s health. Expert Opin Biol Ther 2006; 6: 1223-7.

  55. Stern P. Vacunas VPH Profilácticas. Newsletter on Human Papillomavirus. HPV Today 2008; 14: 4.

  56. Madrid-Marina V, Bermúdez VH. En relación con las vacunas contra el virus del papiloma humano. Salud Pública Mex 2004; 46: 284-5.




2020     |     www.medigraphic.com